New research suggests that statins, a common medication for managing cardiovascular risk, may be linked to more severe menopause symptoms and a higher risk of muscle loss in postmenopausal women.
Statins are widely prescribed to lower cholesterol and reduce the risk of heart disease. However, the U.S. Food and Drug Administration has flagged potential side effects of statin therapy, some of which overlap with common menopause complaints. Researchers sought to examine whether these overlapping effects appear in real-world data.
The study looked at 1,184 postmenopausal women across nine Latin American countries. The researchers assessed menopausal symptoms, risk of sarcopenia, and cognitive function. They compared statin users to non-users, accounting for factors such as age and body weight. Because this was a cross-sectional study, it can identify associations but cannot prove that statins directly cause these outcomes.
Women taking statins were 56% more likely to report severe menopausal symptoms compared to women not on the medication. This difference held even after researchers accounted for other variables. Statin users were also 65% more likely to be at risk for sarcopenia, the gradual loss of muscle mass and physical function that tends to accelerate after menopause. Muscle loss at this stage of life is already a concern due to declining estrogen levels, and it is linked to a higher risk of falls, fractures, and reduced quality of life.
Statin users also reported more intense musculoskeletal symptoms compared to non-users, with 53.1% of users reporting such symptoms versus 33.9% of non-users. This finding is distinct from sarcopenia risk and points to a broader pattern of physical discomfort that may be going unrecognized in women on statins.
On the cognitive side, statin users showed slightly lower scores on tests of delayed memory recall and visuospatial function. No overall link to mild cognitive impairment was found, so these are early signals worth watching, not firm conclusions.
The researchers were careful in their conclusions. They stated that statin-related effects may overlap with menopausal symptoms and contribute to symptom burden during midlife. In other words, the symptoms women attribute to menopause and the side effects associated with statins can look very similar, and in some cases they may be compounding each other. Untangling the two is an open area of research.
This research is not a reason to stop taking statins. For many women, the cardiovascular benefits are real and well-established. Stopping medication without medical guidance can carry serious risks. What this study offers is a fuller picture of what statin therapy might mean for postmenopausal women specifically, a group that has historically been underrepresented in cardiovascular research.
If you are on statins and your menopausal symptoms feel more intense than expected, or if you have noticed changes in muscle strength or physical function, it is worth raising with your doctor. Questions to consider include whether your symptoms are consistent with what you would expect given your statin use, whether you should be screened for muscle loss, whether your current statin is the best option for you, and what you can do to protect your muscles while on statins. Resistance training and getting enough protein are two well-supported ways to preserve muscle mass in midlife.
Statins are life-saving for many people, but their side effects do not always get the attention they deserve, especially in postmenopausal women. This study adds to a growing body of evidence that midlife women deserve more individualized care.
